Based on previous reports, inhibition of the polycomb complex protein BMI-1 might represent an attractive treatment approach for myeloma [19, 20], but therapeutic agents targeting BMI-1 are not available for clinical use so far. Here, BMI1 is linked to plasma cell myeloma.